Protocol Ledger

NCT06817265 · Phase III · RECRUITING

Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy

Interventional Phase III clinical trial protocol NCT06817265 sponsored by Beletalent (Zhuhai) Pharmaceutical Co in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-04-29 Enrollment: 360 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06817265
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)360 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06817265
Protocol FieldVerified Registry Value
NCT IdentifierNCT06817265
Consolidated Lead SponsorBeletalent (Zhuhai) Pharmaceutical Co
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment360 participants (ESTIMATED)
Registered Start Date2025-04-29
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI